Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan
Japanese drug major Daiichi Sankyo (TYO: 4568) has filed an application for approval in Japan to manufacture and market Ranmark SC injection 120mg (denosumab) to treat giant cell tumor of bone (GCTB).
Denosumab was designated as a pharmaceutical for the treatment of rare diseases by Japan’s Ministry of Health, Labor and Welfare in June 2013 for efficacy against GCTB. It is the world’s first fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation, the company said. Daiichi Sankyo has been working on denosumab since 2007, when it acquired the rights from US biotech group Amgen (Nasdaq: AMGN) to develop and market this antibody in Japan.
Other indications
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze